Clinical Trial Update: Bioavailability Study of XS003 (Nilotinib) [Phase 1]

View source ↗

Summary

A Phase 1 bioavailability study of XS003, a formulation of nilotinib, has completed for cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• XS003 (Nilotinib) (nilotinib)

Snippet

Sponsor: Xspray Pharma AB | Conditions: Cancer | Phase 1 | Status: COMPLETED